impact factor
logo
 

One year in review

 

One year in review 2021: Behçet's syndrome


1, 2, 3, 4, 5, 6

 

  1. Division of Rheumatology, Department of Internal Medicine, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey.
  2. Division of Rheumatology, Department of Internal Medicine, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey.
  3. Division of Rheumatology, Department of Internal Medicine, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  5. Division of Ophthalmology, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey.
  6. Division of Rheumatology, Department of Internal Medicine, and Behçet’s Disease Research Centre, Istanbul University-Cerrahpasa, School of Medicine, Istanbul, Turkey. vhamuryudan@yahoo.com

CER14823
2021 Vol.39, N°5 ,Suppl.132
PI 0003, PF 0013
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 34524077 [PubMed]

Received: 21/05/2021
Accepted : 14/07/2021
In Press: 14/09/2021
Published: 06/10/2021

Abstract

This review aims to provide a critical digest of the recent studies that enhance our understanding of Behçet’s syndrome by evaluating time trends, differences in disease course between men and women, and between patients with an early and late disease onset, progress in disease assessment, novel findings on immunopathogenesis and genetics, clinical features and differential diagnosis of eye, vascular, nervous system and gastrointestinal system involvement, and new data on treatment modalities including TNF-alpha, IL-17 and IL-6 inhibitors, tofacitinib, and apremilast, as well as surgical interventions.

Rheumatology Article